This article is more than 5 years old. Information may no longer be current.

Triamcinolone trial to be conducted in Singapore

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SYDNEY, Australia — A clinical trial using triamcinolone to treat age-related macular degeneration is slated to be conducted in Singapore, according to the manufacturer of the drug.

Regenera and the Singapore Eye Research Institute signed a memorandum of understanding to begin clinical trials of Visagen (triamcinolone acetonide, Regenera), a drug in development for the treatment of AMD, according to a press release from the company.

Regenera, based here, said the drug will enter trials in September 2004.

Triamcinolone acetonide, the active ingredient in Visagen, is already widely used off-label by physicians in the United States, where the Regenera Group holds patent rights, the press release noted.